Proinsulin

Long before your fasting glucose creeps up or your HbA1c crosses a threshold, the cells in your pancreas that make insulin can start to falter. One of the earliest visible signs of that strain is in the blood: an unfinished version of insulin called proinsulin that should have been fully processed before release, but escapes when those cells are overworked or damaged.

This is what a proinsulin test captures. It is a window into how well your insulin-making machinery is actually working, not just whether your blood sugar still looks normal today. For people interested in catching metabolic trouble years before it becomes a diagnosis, this marker offers information that a standard glucose or insulin reading does not.

What This Marker Actually Measures

Proinsulin (the full name for this precursor molecule) is built inside the insulin-making cells of your pancreas, called beta cells. In healthy beta cells, proinsulin is routed almost entirely (more than 99%) into the regulated secretory pathway, where it is processed into mature insulin and a connecting fragment before being released. Even so, a meaningful fraction of what circulates as immunoreactive insulin is actually still proinsulin: in healthy adults, the fasting proinsulin-to-insulin ratio is around 15%. When beta cells are stressed, overworked, or damaged, that processing becomes less efficient, and a larger share of unprocessed proinsulin spills into the bloodstream alongside finished insulin.

This test measures the amount of proinsulin circulating in your blood. A higher number suggests your beta cells are producing more than they can properly process, which is one of the earliest fingerprints of metabolic dysfunction. Because the proinsulin signal can appear while your glucose, insulin, and HbA1c still look fine, it may flag a problem before standard panels do.

Type 2 Diabetes Risk

Proinsulin is one of the most consistently validated early predictors of future type 2 diabetes in long-running studies. The Uppsala Longitudinal Study followed 1,224 men starting at age 50 for 27 years; one-third went on to develop type 2 diabetes, and each one-standard-deviation rise in intact proinsulin was linked to roughly 57% higher odds of diabetes (odds ratio 1.57) after accounting for body weight, fasting glucose, and insulin response. A related processing fragment (32-33 split proinsulin) carried even stronger predictive weight (odds ratio about 1.70).

In the Insulin Resistance Atherosclerosis Study, non-diabetic adults were tracked for about five years. Higher intact proinsulin nearly doubled the odds of developing diabetes (odds ratio 1.90, 95% CI 1.57 to 2.30 per standard deviation increase), and the link held even after adjusting for body weight, glucose tolerance, and insulin sensitivity. A Finnish study of 9,396 men over about six years confirmed that both fasting and post-glucose-load proinsulin independently predicted who would progress to diabetes.

That said, proinsulin is not a perfect early warning. Some studies have found that the fasting proinsulin-to-insulin ratio does not clearly separate people with normal versus impaired glucose tolerance, and in mixed populations proinsulin and the ratio can be relatively weak predictors of who eventually develops diabetes. The signal is most useful as one input among several, not a standalone screen.

What this means for you: an elevated proinsulin level is one of the few signals that can put a number on beta-cell strain before glucose tolerance breaks down. If your fasting glucose, HbA1c, and insulin all look unremarkable, a high proinsulin can still suggest the underlying machinery is being pushed harder than it should be, though it is best interpreted alongside other metabolic markers.

Cardiovascular Disease and Mortality

The link between proinsulin and heart disease appears independent of diabetes itself. A meta-analysis of prospective studies found that people in the top third of proinsulin had roughly 2.2 times the heart disease risk of those in the bottom third (odds ratio 2.23).

In the same 27-year Uppsala cohort, men had about 47% higher risk of dying from coronary heart disease per standard-deviation increase in proinsulin (hazard ratio 1.47), even after adjusting for smoking, blood pressure, LDL-to-HDL ratio, body weight, triglycerides, and fasting glucose. Notably, regular insulin levels did not predict the same outcome. The 11-year Hoorn Study found each interquartile-range rise in fasting proinsulin was tied to roughly 21% higher all-cause mortality (hazard ratio 1.21) and 33% higher cardiovascular mortality (hazard ratio 1.33).

One caveat: a Mendelian randomization analysis using genetic variants linked to proinsulin found that proinsulin itself is unlikely to be a direct cause of subclinical vascular changes. Proinsulin may largely be a marker of underlying beta-cell stress and insulin resistance that drives cardiovascular risk, rather than a causal mediator in its own right.

Stroke risk follows a similar pattern. In a Swedish follow-up of 1,151 elderly men, each standard-deviation increase in fasting proinsulin was associated with about 22% higher stroke risk (hazard ratio 1.22) after adjusting for diabetes, hypertension, atrial fibrillation, cholesterol, and smoking. A separate Swedish case-referent study found people with high proinsulin had about 3.4 times the stroke risk of those with low levels.

Insulinoma and Hypoglycemia Workups

In a different clinical context, proinsulin is among the most accurate markers for diagnosing an insulinoma, a rare insulin-producing tumor. During a supervised fast, an end-of-fast proinsulin level at or above roughly 22 to 27 pmol/L distinguishes insulinoma cases from healthy people with sensitivity and specificity approaching 100% in published series. At milder degrees of low blood sugar, proinsulin even outperforms insulin and C-peptide, the connecting fragment released with insulin (about 90% sensitivity versus 85% for the other two).

If you are being worked up for unexplained low blood sugar, proinsulin testing alongside glucose, insulin, C-peptide, and a sulfonylurea screen is the standard panel that distinguishes a real tumor from medication effects or other causes.

Why One Reading Is Not Enough

Proinsulin has one of the highest biological variabilities of any common metabolic marker. In a large general-population study, 95% of random test-retest differences for fasting proinsulin fell within about 100% of the median value. Most of that variation is biological, not assay-related, which means a single reading can be misleading.

This is why a single proinsulin number is far less useful than a trend. Getting a baseline and then retesting in 3 to 6 months if you are making changes to your weight, exercise, or medication (and at least annually after that) is a reasonable approach, though it is not based on any formal guideline. Two or three readings spaced over months will tell you something a one-time draw cannot: whether your beta cells are quietly drifting toward dysfunction or holding steady.

Proinsulin levels in people with established autoimmune (type 1) diabetes have been shown to remain relatively stable across 4-year follow-ups. That is a different clinical context than the prevention-focused use here, but it supports the broader point that once a person's pattern is established, repeated measurements over time give a reliable picture of beta-cell behavior.

When Results Can Be Misleading

• Fasting status: proinsulin rises substantially after a glucose load. A non-fasting draw can easily look elevated when nothing is wrong.
• Corticosteroid use: drugs like prednisone can more than double the proinsulin-to-insulin ratio within a week (from about 14.7% to 33.9%), independent of any underlying diabetes. Growth hormone treatment produces an even bigger artifact (to about 40.9%). If you are on these medications, your reading reflects the drug effect, not your true beta-cell state.
• Acute illness or surgical stress: any state that increases workload on your beta cells can transiently inflate the proinsulin-to-insulin ratio, especially after meals. Wait until you are out of the acute episode before testing.
• Assay variation: there is no universal standard for proinsulin measurement, and results vary between labs. If you are tracking trends, use the same lab each time.

What to Do With an Elevated Result

An elevated proinsulin level without any other abnormal lab is not a diagnosis. It is a signal worth investigating. The right next step depends on what else is going on. If your glucose tolerance and HbA1c are still normal, an elevated proinsulin combined with high waist circumference, elevated triglycerides, or rising fasting insulin suggests early insulin resistance and beta-cell strain. The pattern, not the single number, drives the action.

Companion tests that make proinsulin actionable include fasting glucose, HbA1c, fasting insulin (to calculate HOMA-IR, a measure of insulin resistance), C-peptide, and a standard lipid panel. If your full metabolic picture looks worrisome, consider asking for an oral glucose tolerance test and a referral to a clinician who specializes in metabolic health. If proinsulin is elevated in the context of unexplained low blood sugar, the workup pivots to insulinoma evaluation with a supervised fast.

For most people, the value of catching this signal early is the time it buys you to intervene before glucose tolerance fails.

A Note on How This Test Is Currently Used

In conventional clinical practice, proinsulin testing is reserved for insulinoma workups, and major guidelines explicitly state that proinsulin measurement is not recommended for routine diabetes management because it has not been shown to change how a diagnosed condition is treated. From a prevention standpoint, the calculus is different. Proinsulin may offer a glimpse of beta-cell function before standard panels would catch a problem, and even modest evidence of early dysfunction can be actionable for someone interested in staying ahead of metabolic disease. Treat it as an exploratory but informative addition to a more conventional metabolic workup, not a replacement for it.